Specifications CD9 Recombinant Protein
Description
Documents
QC & Validation
Lorvotuzumab Biosimilar - Anti-NCAM1, CD56 mAb binds to CD56 Recombinant Protein in indirect ELISA Assay
Immobilized CD56 Recombinant Protein (cat. No.PX-P4123) at 0.5µg/mL (100µL/well) can bind to Lorvotuzumab Biosimilar - Anti-NCAM1, CD56 mAb (cat. No.PX-TA1047) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450
3D Representation
Publications
- Nahide Zeren Arda Ozturk, Oliwia Barbara Majchrzak, Gianluca Ulivi, Petek Ballar Kirmizibayrak, Gerrit Borchard, Viorica Patrulea, Ozgen Ozer,Fully synthetic, nature-inspired exosome-mimetics for melanoma therapy, International Journal of Pharmaceutics, Volume 693, 2026, 126715, ISSN 0378-5173, https://doi.org/10.1016/j.ijpharm.2026.126715




There are no reviews yet.